BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11155357)

  • 1. The immune response to vaccinia virus is significantly reduced after scarification with TK- recombinants as compared to wild-type virus.
    Phillpotts RJ; Lescott T; Gates AJ; Jones L
    Acta Virol; 2000; 44(3):151-6. PubMed ID: 11155357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinia virus recombinants encoding the truncated structural gene region of Venezuelan equine encephalitis virus (VEEV) give solid protection against peripheral challenge but only partial protection against airborne challenge with virulent VEEV.
    Phillpotts RJ; Lescott TL; Jacobs SC
    Acta Virol; 2000 Oct; 44(5):233-9. PubMed ID: 11252667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
    Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
    Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
    Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
    Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic properties of vaccinia virus and of the virus recombinant strains expressing heterologous genes.
    Chelyapov NV; Antonova TP; Yanova NN; Chernos VI
    Acta Virol; 1988 Sep; 32(5):409-16. PubMed ID: 2904735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
    Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
    Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
    Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
    Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals.
    Lodmell DL; Esposito JJ; Ewalt LC
    Vaccine; 2004 Sep; 22(25-26):3329-33. PubMed ID: 15308356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
    Breathnach CC; Clark HJ; Clark RC; Olsen CW; Townsend HG; Lunn DP
    Vaccine; 2006 Feb; 24(8):1180-90. PubMed ID: 16194586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant forms of the F protein of human respiratory syncytial (RS) virus induce a cytotoxic T lymphocyte response but not a neutralizing antibody response and only transient resistance to RS virus infection.
    Gaddum RM; Cook RS; Wyld SG; López JA; Bustos R; Melero JA; Taylor G
    J Gen Virol; 1996 Jun; 77 ( Pt 6)():1239-48. PubMed ID: 8683212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
    J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlling orthopoxvirus infections--200 years after Jenner's revolutionary immunization.
    Niemiałtowski MG; Toka FN; Malicka E; Gieryńska ; Spohr de Faundez I; Schollenberger A
    Arch Immunol Ther Exp (Warsz); 1996; 44(5-6):373-8. PubMed ID: 9017154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW; Josleyn MD; Hooper JW
    Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of mice with replication-defective human immunodeficiency virus induces cellular and humoral immunity and protects against vaccinia virus-gag challenge.
    Baliga CS; van Maanen M; Chastain M; Sutton RE
    Mol Ther; 2006 Sep; 14(3):432-41. PubMed ID: 16713742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.
    Weyer J; Rupprecht CE; Mans J; Viljoen GJ; Nel LH
    Vaccine; 2007 May; 25(21):4213-22. PubMed ID: 17434244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
    Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.